Acute liver injury following Garcinia cambogia weight-loss supplementation: case series and literature review

Original Citation:
Acute liver injury following Garcinia cambogia weight-loss supplementation: case series and literature review / Crescioli, Giada; Lombardi, Niccolò; Bettiol, Alessandra; Marconi, Ettore; Risaliti, Filippo; Bertoni, Michele; Menniti Ippolito, Francesca; Maggini, Valentina; Gallo, Eugenia; Firenzuoli, Fabio; Vannacci, Alfredo. - In: INTERNAL AND EMERGENCY MEDICINE. - ISSN 1828-0447. - ELETTRONICO. - 13:(2018), pp. 857-872. [10.1007/s11739-018-1880-4]

Availability:
This version is available at: 2158/1244214 since: 2022-05-04T12:37:12Z

Published version:
DOI: 10.1007/s11739-018-1880-4

Terms of use:
Open Access
La pubblicazione è resa disponibile sotto le norme e i termini della licenza di deposito, secondo quanto stabilito dalla Policy per l'accesso aperto dell'Università degli Studi di Firenze (https://www.sba.unifi.it/upload/policy-oa-2016-1.pdf)

Publisher copyright claim:

(Article begins on next page)
Acute liver injury following *Garcinia cambogia* weight-loss supplementation: case series and literature review

Giada Crescioli¹ · Niccolò Lombardi¹ · Alessandra Bettiol¹ · Ettore Marconi¹ · Filippo Risaliti² · Michele Bertoni² · Francesca Menniti Ippolito³ · Valentina Maggini⁴,⁵ · Eugenia Gallo⁴,⁵ · Fabio Firenzuoli⁵ · Alfredo Vannacci¹

Received: 8 March 2018 / Accepted: 17 May 2018 © SIMI 2018

**Abstract**

Herbal weight-loss supplements are sold as self-medication products, and are often used under the misconception that their natural origin guarantees their safety. Food supplements are not required to provide any benefit/risk profile evaluation before marketing; however, possible risks associated with use of herbal extracts in food supplements are becoming more and more documented in the literature. Some herbs are listed as the leading cause of herb-induced liver injury, with a severe or potentially lethal clinical course, and unpredictable herb–drug interactions. *Garcinia cambogia* (GC) extract and GC-containing products are some of the most popular dietary supplements currently marketed for weight loss. Here, we present four cases of acute liver failure in women taking GC extract for weight loss, and a literature review of clinical evidences about hepatic toxicity in patients taking dietary supplements containing GC extract.

**Keywords** Adverse events · Dietary supplements · *Garcinia cambogia* · Herb-induced liver injury · Hydroxycitric acid · Liver transplantation · Weight-loss supplements

**Introduction**

Obesity has reached epidemic proportions globally, with at least 2.8 million people dying each year as a result of being overweight or obese [1]. Nonetheless, very few drugs are registered for this indication, while many dietary supplements containing medicinal plants are promoted for weight loss [2]. Their use is widespread and increasing in many European countries and in the United States, while the efficacy and safety data of these preparations are not required before marketing. Moreover, many claims cited by supplements are unsupported and inadequately regulated [3].

Medicinal plants and natural substances commonly used for weight loss include *Camellia sinensis, Amorphophallus konjac* (glucomannan), 1,3-dimethylamylamine, chitosan, usnic acid, *Cyamopsis tetragonolobus*, conjugate linoleic acid, *Ephedra, Garcinia cambogia* (GC), *Plantago ovata*, and *Citrus aurantium* [4].

Herbal weight-loss supplements are generally used as self-medication under the misconception that their natural origin guarantees their safety [5]. As described by Pajor and colleagues (2017), users and non-users of dietary supplements consider these products safe, and assign the occurrence of possible adverse effects (AEs) more to the...
consumer status (e.g., excessive use, being ill, etc.) than to the product characteristics [6]. Indeed, some herbal chemicals have been related to herb-induced liver injury (HILI) with a severe or potentially lethal clinical course, leading to emergency department (ED) visit and liver transplant [7]. Regarding the herbal extract of GC, the main active component is the hydroxycitric acid (HCA), which acts as potential supplement to weight control by causing appetite suppression, and reducing the body’s ability to form adipose tissue [8]. Nevertheless, there are contrasting findings on HCA safety [9], and several aspects on its effectiveness in weight-loss control are still poorly investigated [10].

Given that, regulations and pharmacovigilance regarding herbal products are incomplete and need to be improved [11].

To shed light on the benefit/risk ratio of the use of GC extract as dietary supplement [10], we present four cases of acute liver failure in women taking GC extract for weight loss, and a literature review of the clinical evidences on the onset of hepatic toxicity in patients taking dietary supplements containing GC extract.

### Case series

Within the Italian Surveillance System of Natural Health Products, set up in 2002 and coordinated by the Italian National Institute of Health [12], a multidisciplinary group of experts collected the suspected AEs related to dietary supplements containing GC. In particular, AEs related to acute hepatotoxicity and leading to ED visit were evaluated. From April 2002 to December 2017, out of a total of 1510 reports, 14 concerned AEs to weight-loss supplements containing GC, 6 reported acute liver toxicity. The first case was registered in 2005 and subsequently documented [13]; nevertheless, another four cases occurred, and a description is included below. One case was excluded because the patient had been exposed to several dietary supplements other than GC, and it was difficult to clearly define the causality assessment between herbal intake and related hepatotoxicity. Figure 1 shows principal hepatic parameters measured for each patient at the ED visit.

### Case 1

A 61-year-old woman presented to ED with symptoms of 10-day abdominal pain, nausea, progressive weakness, jaundice, dark urine, and acholic stools. The patient’s anamnesis denoted cholecystectomy, mixed dyslipidemia, and hypothyroidism in treatment with levothyroxine. There was no history of alcoholism or exposure to hepatotoxins; she also denied paracetamol abuse.

She reported taking one envelope/daily of SUPER ANANAS SLIM®, for a period of 2 months to lose weight. This additional feed contained extracts of GC (HCA 60%), Ananas comosus (bromelain 334 GDU, Gelatin Dissolving Units), and Ilex paraguariensis (caffeine 2%).

Laboratory tests performed during the ED visit revealed that alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TB), direct bilirubin, albumin, alkaline phosphatase (ALP), and gamma glutamyl transferase (GGT) values were out of the normal range. International normalized ratio (INR) at ED admission was in range (INR 1.6, range 0.83–1.9). Table 1 summarizes the trend of the main liver function indices from the acute phase after ED admission to the follow-up.

A 3-month prior routine check-up had found such parameters to be normal. The serum was negative for hepatitis viruses or autoantibodies as well as for Wilson’s disease. Abdominal ultrasound, cholangio-magnetic resonance imaging (MRI), and portal vessel’s Doppler were normal, and did not reveal steatosis.

The abdominal computed tomography scan revealed a small peritoneal effusion, perihepatic lymphadenopathy, and a hepatic biopsy which was consistent with cholestatic hepatitis. The progressive increase in TB levels up to 22.5 mg/dL was treated by clinicians with two sessions of plasmapheresis. Later, the levels of TB declined. Four weeks after the...
cessation of the GC-containing supplement intake, patient symptoms and liver function tests gradually improved, and she was discharged with no need for a liver transplant. Four months later, the levels of the above-mentioned laboratory tests reverted to normal values.

Clinicians also use the recently updated hepatotoxicity specific Council for International Organizations of Medical Sciences (CIOMS) scale as a tool to confirm the HILI diagnosis [14]. The total score and resulting causality grading for this case was 7 (score range 6–8), consistent with a probable diagnosis of HILI.

**Case 2**

A 39-year-old woman presented to the ED with symptoms of jaundice, asthenia, loss of appetite, and right hypochondrial pain. Her anamnesis denoted arterial hypertension, obesity (body mass index, BMI 44.9), and hiatal hernia. Current medications at the time of admission were methyldopa 500 mg/die, domperidone 10 mg three times per day and omeprazole 20 mg two capsules per day.

She also reported taking two dietary supplements for weight loss recommended by her dietitian. The first, OBLESS®, contained for each capsule: C. aurantium 140 mg of extract 10% (14 mg of synephrine), GC (72 mg of HCA), Orthosiphon stamineus (0.2 mg of sinensetin), and Griffonia simplicifolia (75 mg of 5-hydroxy-\(\tau\)-tryptophan). The second was a magistral preparation containing for each capsule: C. aurantium 350 mg of extract 6% (21 mg of synephrine), Rhodiola rosea 150 mg extract, and O. stamineus 200 mg extract. The patient declared that she had been taking the first dietary supplement for the previous month (1 capsule/day) and the magistral preparation for 15 days (1 capsule/day), simultaneously.

Laboratory tests performed in the ED revealed that principal hepatic markers (ALT, AST, and TB) were out of the normal ranges (Fig. 1). Moreover, for this patient, the following liver indices were also available: direct bilirubin (13.2 mg/dL; range 0–0.25 mg/dL), ALP (158 UI/L; range 42–98 UI/L), GGT (80 UI/L; range 7–32 UI/L), lactate dehydrogenase (399 UI/L; range 140–180 UI/L), C-reactive protein (1.91 mg/dL; range < 0.5 mg/dL), and mean corpuscular volume (76 fl/red cell; range 80–96 fl/red cell). Blood coagulation parameters and hemoglobin (Hb 13.2 g/dL) were in range. Serology was negative for hepatitis viruses, cytomegalovirus, and varicella–zoster virus. On the contrary, nonspecific antinuclear antibodies and biliary antibodies were positive. Abdominal ultrasound was normal, and did not reveal steatosis. Liver biopsy was not performed.

During the hospital stay, after the cessation of dietary supplements and concomitant medications intake, levels of TB spontaneously declined, and her symptoms and liver function tests gradually improved. After 12 days of hospitalisation, the patient was discharged with no need of supplementary therapies, and a diagnosis of acute cholestatic hepatitis related to the consumption of OBLESS® was made. With regard to hepatotoxicity, a role of the simultaneous use of methyldopa, high dose of synephrine and HCA could not be excluded, although the total score and resulting causality grading for this case was 6, consistent with probable diagnosis of HILI.

**Case 3**

A 47-year-old woman was admitted to the ED with symptoms of severe abdominal pain (right hypochondrial). Her anamnesis denoted hypothyroidism (treated with levothyroxine 100 µg/day), arterial hypertension (treated with
enalapril 20 mg/day), and mild obesity. She also reported taking 2 capsules/day of THERMO GIALLO®, a dietary supplement as self-medication for weight control. This product contains chromium 50 µg and GC 400 mg of extract 50% (200 mg of HCA), for each capsule. The patient reported that she had been taking this supplement for the previous month (2 capsules/day). Laboratory tests performed during the ED visit revealed a mild elevation of liver parameters: AST, TB, and ALT (Fig. 1). Serology was negative for hepatitis viruses or autoantibodies. No clinical evidences of steatosis were observed, and liver biopsy was not performed.

During the hospital stay, after the cessation of weight-loss supplement, the levels of TB spontaneously declined, and her symptoms and liver function tests rapidly improved, without the need of therapies. The patient was discharged with a diagnosis of acute hepatitis, and the total score and resulting causality grading was 6, consistent with probable diagnosis of HILI.

Case 4

A 52-year-old woman was admitted to the ED, and diagnosed with acute hepatitis. No significant diseases and medication therapies were reported in anamnesis. However, she was taking two JILL COOPER BE SLIM ® products (1 capsule/day for each product) for weight control, containing GC 400 mg of extract 60% (240 mg of HCA) and Green Coffee 400 mg of extract 50% (200 mg of chlorogenic acid), respectively. The patient declared that she bought these supplements on a television channel, and she used them for the previous month before the ED visit.

Laboratory tests revealed a mild elevation of principal liver parameters: AST, TB, ALT (Fig. 1). Moreover, for this patient, the following liver indices were also available: GGT (223 UI/L), and ALP (204 UI/L). Serologies for hepatitis viruses and autoantibodies were also negative. No clinical evidences of steatosis were observed, and liver biopsy was not performed.

During the following days, after the cessation of weight-loss supplements, liver parameters spontaneously declined, and acute hepatitis completely resolved with no need of supplementary therapies. The total score grading for this case was consistent with probable diagnosis of HILI (total score 6).

Literature review

Data for this review were obtained by searching Medline or PubMed with a search strategy that included four domains: one related to GC, one to its use in humans for weight control, one related to safety, and one related to dietary supplements. We included only case reports and case series, carried out in humans, and published in a scientific journal in the database of Science Citation Index or Medline between January 2000, and October 2017. We finally selected 24 case reports and 8 case series reporting AEs in a total of 66 patients after GC extract consumption. Once the articles had been selected, the following significant data were extracted: article, country, number of patients, gender, age (years), adverse events, diagnosis, symptoms, clinical outcome, clinical history, concomitant drugs, and exposure to GC before symptoms’ onset. Characteristics of the analyzed studies are reported in Table 2.

Five studies report single cases of myocarditis, cardiomyopathy, serotonin toxicity, hypoglycaemia, and thrombocytopenic purpura [15–19]. Two patients presented acute pancreatitis and diabetic ketoacidosis [20, 21], three patients experienced rhabdomyolysis [22–24], and in five studies, the authors describe AEs of mania and multiple psychotic symptoms [25–29]. Most patients were women (62%) with no relevant medical history. Seventeen studies out of 32 describe cases of acute liver injury, liver failure, and hepatotoxicity, observed in 50 patients who consumed GC dietary supplements or GC pure extract [13, 30–45].

All patients with hepatic AEs consumed their food supplements following producers’ indications, and developed similar symptoms. In particular, jaundice, weakness, abdominal pain, dark urine, nausea, and vomiting were the most reported AEs. Symptoms’ onset and clinical outcome differed among cases. In fact, some patients were exposed to GC only for a few days or weeks, other patients took their dietary supplement for more than 1 year. Moreover, 38 patients improved, while 8 subjects needed a liver transplantation. One patient was diagnosed with liver cirrhosis and two patients died. The first one, a 45-year-old Italian woman, was taking montelukast because of chronic asthma (5-year treatment) and developed a rapid progressive liver failure after 7-day consumption of two dietary supplements containing GC and C. aurantium, taken simultaneously [13]. Authors postulated that HCA augmented the liver toxicity proper of montelukast. The second patient died because of complications following liver transplantation [33]. Laboratory tests performed during the ED visit showed similar liver serum indices among patients with hepatic AEs. Liver serum values, when reported in more than five studies, are listed in Supplementary Table 1.

In two case reports and five case series, authors used several algorithms and scales to estimate the causality assessment between observed AEs and GC consumption. In four studies CIOMS criteria were used, with a total of 1 possible, 2 certain, and 12 probable cases [31, 40, 42, 44].

Elinav and colleagues [33] using WHO criteria [46] to define causality assessment of AEs related to GC consumption, address three cases as certain, six as probable, and three as possible. Another case [45] was defined as probable
<table>
<thead>
<tr>
<th>Article</th>
<th>Country</th>
<th>No of patients</th>
<th>Gender</th>
<th>Age (years)</th>
<th>Adverse event and diagnosis</th>
<th>Symptoms</th>
<th>Clinical outcome</th>
<th>Clinical history</th>
<th>Concomitant drugs</th>
<th>Exposure to GC before symptoms onset</th>
</tr>
</thead>
<tbody>
<tr>
<td>Actis, 2007 [13]</td>
<td>Italy</td>
<td>1</td>
<td>F</td>
<td>45</td>
<td>Fatal liver failure</td>
<td>Nausea, vomiting, malaise, jaundice</td>
<td>Death</td>
<td>Asthma; obesity</td>
<td>Montelukast</td>
<td>1 w</td>
</tr>
<tr>
<td>Allen, 2014 [15]</td>
<td>USA</td>
<td>1</td>
<td>F</td>
<td>48</td>
<td>Acute necrotizing eosinophilic myocarditis</td>
<td>Light-headedness, hypotension, chest heaviness, presyncopal event, tachycardia</td>
<td>Improvement</td>
<td>No medical history</td>
<td>None</td>
<td>2.5 w</td>
</tr>
<tr>
<td>Bystrak, 2017 [20]</td>
<td>USA</td>
<td>1</td>
<td>F</td>
<td>56</td>
<td>Diabetic ketoacidosis, pancreatitis, cardiomyopathy</td>
<td>Mild abdominal pain, vomiting, lethargy, confusion, peri-pancreatic stranding, pancreatic atrophy, tachycardia</td>
<td>Hospitalization</td>
<td>Diabetes mellitus; hypertension; hepatitis C infection; opioid abuse 18 years before the event; hyperlipidemia; anxiety</td>
<td>Insulin glargine 75 U daily; atorvastatin 20 mg daily; lisinopril 5 mg daily; hydrochlorothiazide 12.5 mg daily; metformin 2000 mg daily; metoprolol 25 mg daily; aspirin 81 mg daily; methadone 125 mg daily; diazepam 10 mg daily; dietary supplement with <em>Irvingia gabonensis</em> or African mango</td>
<td>1 mo (6 tablets daily)</td>
</tr>
<tr>
<td>Article</td>
<td>Country</td>
<td>No of patients</td>
<td>Gender</td>
<td>Age (years)</td>
<td>Adverse event and diagnosis</td>
<td>Symptoms</td>
<td>Clinical outcome</td>
<td>Clinical history</td>
<td>Concomitant drugs</td>
<td>Exposure to GC before symptoms onset</td>
</tr>
<tr>
<td>----------------------</td>
<td>---------</td>
<td>----------------</td>
<td>--------</td>
<td>-------------</td>
<td>-----------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>------------------</td>
<td>------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>---------------------------------------</td>
</tr>
<tr>
<td>Chen, 2010 [30]</td>
<td>USA</td>
<td>3</td>
<td>F</td>
<td>31</td>
<td>Acute liver injury (DILI); multi-lobular necrosis, fulminant hepatitis</td>
<td>Fatigue, jaundice, and nausea, scleral icterus, and mild upper quadrant tenderness</td>
<td>Improvement</td>
<td>No medical history</td>
<td>None</td>
<td>1 year (2 tablets daily)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>F</td>
<td>37</td>
<td>Acute liver injury (DILI); centrolobular and periportal necrotizing hepatitis, bridging fibrosis</td>
<td>Diffuse abdominal pain, mild nausea, painless jaundice</td>
<td>Improvement</td>
<td>No medical history</td>
<td>None</td>
<td>3 mo</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>F</td>
<td>53</td>
<td>Acute liver injury (DILI); cholestasis and drug-induced hepatitis</td>
<td>Painless jaundice, pruritus, scleral icterus, with evidence of excoriations</td>
<td>Improvement</td>
<td>No medical history</td>
<td>None</td>
<td>4 mo</td>
</tr>
<tr>
<td>Corey, 2016 [31]</td>
<td>USA</td>
<td>1</td>
<td>F</td>
<td>52</td>
<td>Acute liver failure; shrunken nodular liver; collapsing necrosis</td>
<td>Decrease appetite, worsening fatigue, intermittent confusion, jaundice</td>
<td>Liver transplantation</td>
<td>No medical history</td>
<td>Topical hormone cream (β-estrogen and progesterone); melatonin; dicyclomine; antifungal nail oil</td>
<td>3.5 w (2 tablets daily)</td>
</tr>
<tr>
<td>Cotovio, 2017 [25]</td>
<td>USA</td>
<td>1</td>
<td>F</td>
<td>51</td>
<td>Hypomania</td>
<td>Irritability, agitation, increased energy, decrease need for sleep</td>
<td>Full remission of all symptoms</td>
<td>Bipolar disorder type I</td>
<td>Valproic acid 1250 mg/day; paroxetine 20 mg/day</td>
<td>2 w</td>
</tr>
<tr>
<td>Article</td>
<td>Country</td>
<td>No of patients</td>
<td>Gender</td>
<td>Age (years)</td>
<td>Adverse event and diagnosis</td>
<td>Symptoms</td>
<td>Clinical outcome</td>
<td>Clinical history</td>
<td>Concomitant drugs</td>
<td>Exposure to GC before symptoms onset</td>
</tr>
<tr>
<td>-----------------</td>
<td>---------</td>
<td>----------------</td>
<td>--------</td>
<td>-------------</td>
<td>-----------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>------------------------</td>
<td>-----------------</td>
<td>-------------------------------------------------------------------------------------</td>
<td>--------------------------------------</td>
</tr>
<tr>
<td>Dara, 2008 [32]</td>
<td>USA</td>
<td>2</td>
<td>F</td>
<td>40</td>
<td>Hepatotoxicity</td>
<td>Crampy, mid-epigastric abdominal pain, diarrhea, fever, chills, nausea and vomiting, anorexia, profound fatigue</td>
<td>Improvement</td>
<td>Hypothyroidism</td>
<td>Levothyroxine</td>
<td>1 w (6 pills daily)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>F</td>
<td>33</td>
<td>Acute hepatitis</td>
<td>Jaundice, nausea, crampy abdominal pain, alcoholic stools, dark-colored urine, pruritus, profound fatigue</td>
<td>Improvement</td>
<td>Pituitary adenoma</td>
<td>Ortho-Novum® contraceptive (2.5 years)</td>
<td>2 w</td>
</tr>
<tr>
<td>Dehoney, 2009</td>
<td>USA</td>
<td>1</td>
<td>M</td>
<td>18</td>
<td>Rhabdomyolysis</td>
<td>Bilateral leg pain, weakness, leg tenderness</td>
<td>Improvement after 6 L of 0.9% sodium chloride i.v.</td>
<td>NR</td>
<td>Naproxen 220 mg; Adderall® (dextroamphetamine-amphetamine salts) 15 mg monthly per os; hydrocodone-acetaminophen; cyclobenzaprine 4 caplets daily</td>
<td></td>
</tr>
<tr>
<td>Elinav, 2007</td>
<td>Israel</td>
<td>12</td>
<td>11 F 1 M</td>
<td>Mean 49.5, range 23–78</td>
<td>Acute idiopathic liver injury in association with Herbalife® consumption</td>
<td>Fatigue, jaundice, weight loss (11 patients)</td>
<td>11 pts improved; 1 pt died after liver transplantation</td>
<td>1 pt positive for hepatitis B; 1 pt with primary biliary cirrhosis; 10 pts with no relevant medical history</td>
<td>1 pt aspirin, metformin, statins; 1 pt α-adrenergic blocker; 2 pts hormone replacement therapy; 1 pt ursodeoxycholic acid; 1 pt oral contraceptives; 1 pt bisphosphonates, aspirin; 5 pts none</td>
<td>Mean ± SD 11.9 ± 11.1 mo</td>
</tr>
<tr>
<td>Article</td>
<td>Country</td>
<td>No of patients</td>
<td>Gender</td>
<td>Age (years)</td>
<td>Adverse event and diagnosis</td>
<td>Symptoms</td>
<td>Clinical outcome</td>
<td>Clinical history</td>
<td>Concomitant drugs</td>
<td>Exposure to GC before symptoms onset</td>
</tr>
<tr>
<td>--------------------</td>
<td>---------</td>
<td>----------------</td>
<td>--------</td>
<td>-------------</td>
<td>-----------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>----------------------------------------</td>
<td>-------------------</td>
<td>------------------------------------</td>
</tr>
<tr>
<td>Fong, 2010 [34]</td>
<td>USA</td>
<td>8</td>
<td>2 F 6 M</td>
<td>Mean 30.9; range 17–54</td>
<td>Severe liver injury</td>
<td>Jaundice (all pts), fatigue (6 pts), nausea and vomiting (all pts), abdominal pain (4 pts)</td>
<td>3 pts improved after liver transplantation; 5 pts improved</td>
<td>All pts with no relevant medical history</td>
<td>1 pt prednisone</td>
<td>Median 6 w 1 pt 52 w 1 pt 104 w</td>
</tr>
<tr>
<td>Hendrickson, 2016 [29]</td>
<td>USA</td>
<td>3</td>
<td>M 50</td>
<td>Mania</td>
<td>Grandiosity, irritability, pressured speech, excessive spending, increased social activity, decreased need for sleep</td>
<td>Improvement; hospital discharge with olanzapine and valproic acid therapy</td>
<td>Bipolar disorder type I</td>
<td>NR</td>
<td>2 mo (2 pills daily)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>M 25</td>
<td>Mania; psychosis; bipolar disorder type I</td>
<td>Infiltrated self-esteem, grandiosity, decreased need for sleep, increased activities, excessive spending, pressured speech, paranoia, religious delusions</td>
<td>Improvement; hospital discharge with olanzapine and valproic acid therapy</td>
<td>No medical history</td>
<td>NR</td>
<td>2 mo (1–2 pills daily)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>F 34</td>
<td>Mania</td>
<td>Irritability, pressured speech, decreased need for sleep, agitation</td>
<td>Improvement; hospital discharge with low-dose lorazepam therapy</td>
<td>Bipolar disorder type II; past SSRI-induced hypomania</td>
<td>Aripiprazole; bupropion; topiramate</td>
<td>4–6 w</td>
<td></td>
</tr>
<tr>
<td>Hines, 2015 [23]</td>
<td>USA</td>
<td>1</td>
<td>M 40</td>
<td>Severe rhabdomyolysis</td>
<td>Muscle soreness, dark urine</td>
<td>Improvement</td>
<td>No medical history</td>
<td>None</td>
<td>2 w (1 capsule daily)</td>
<td></td>
</tr>
<tr>
<td>Jones, 2007 [35]</td>
<td>USA</td>
<td>1</td>
<td>M 19</td>
<td>Acute liver injury</td>
<td>Nausea, vomiting, jaundice, scleral icterus</td>
<td>Improvement</td>
<td>No medical history</td>
<td>None</td>
<td>4 mo</td>
<td></td>
</tr>
<tr>
<td>Article</td>
<td>Country</td>
<td>No of patients</td>
<td>Gender</td>
<td>Age (years)</td>
<td>Adverse event and diagnosis</td>
<td>Symptoms</td>
<td>Clinical outcome</td>
<td>Clinical history</td>
<td>Concomitant drugs</td>
<td>Exposure to GC before symptoms onset</td>
</tr>
<tr>
<td>-----------------</td>
<td>---------</td>
<td>----------------</td>
<td>--------</td>
<td>-------------</td>
<td>------------------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>------------------</td>
<td>------------------</td>
<td>-------------------</td>
<td>-------------------------------</td>
</tr>
<tr>
<td>Joseph, 2014</td>
<td>USA</td>
<td>1</td>
<td>F</td>
<td>51</td>
<td>Cardiomyopathy; hypokinesis of the left ventricle</td>
<td>Shortness of breath, new onset of palpitations, hypertension</td>
<td>Improvement</td>
<td>No medical history</td>
<td>None</td>
<td>1 w</td>
</tr>
<tr>
<td>Kotadia, 2016</td>
<td>USA</td>
<td>1</td>
<td>F</td>
<td>36</td>
<td>Hepatotoxicity; liver mild echotexture coarsening; small ascites</td>
<td>Low-grade fever, nausea, vomiting, abdominal pain, scleral icterus, malaise, fatigue, anorexia, jaundice, tender hepatomegaly</td>
<td>Improvement</td>
<td>No medical history</td>
<td>None</td>
<td>4 w</td>
</tr>
<tr>
<td>Lopez, 2014</td>
<td>USA</td>
<td>1</td>
<td>F</td>
<td>35</td>
<td>Serotonin Toxicity</td>
<td>Stuttering speech, profuse sweating, hypertension, tachycardia, diaphoresis, spontaneous ankle clonus</td>
<td>Improvement</td>
<td>Chronic pain syndrome</td>
<td>Oxycodone and cannabis for chronic pain syndrome; escitalopram 20 mg for 1 year; sertraline 50 mg/day 1.5 w prior to admission; baclofen; gabapentin; omeprazole; oxycodone; silodosin; solifenacin; diphenhydramine</td>
<td>2–3 mo (6 capsules daily)</td>
</tr>
<tr>
<td>Lunsford, 2016</td>
<td>USA</td>
<td>1</td>
<td>M</td>
<td>34</td>
<td>Acute liver failure; submassive necrosis</td>
<td>Nausea, vomiting, abdominal pain, dark urine, asterixis, jaundice, confusion</td>
<td>Liver transplantation</td>
<td>No medical history</td>
<td>NR</td>
<td>5 mo (6 capsules daily)</td>
</tr>
<tr>
<td>Mansi, 2004</td>
<td>USA</td>
<td>1</td>
<td>F</td>
<td>54</td>
<td>Rhabdomyolysis</td>
<td>Spasmodic chest pain, breath shortness</td>
<td>Improvement</td>
<td>Moderate obesity</td>
<td>NR</td>
<td>3 h</td>
</tr>
<tr>
<td>Article</td>
<td>Country</td>
<td>No of patients</td>
<td>Gender</td>
<td>Age (years)</td>
<td>Adverse event and diagnosis</td>
<td>Symptoms</td>
<td>Clinical outcome</td>
<td>Clinical history</td>
<td>Concomitant drugs</td>
<td>Exposure to GC before symptoms onset</td>
</tr>
<tr>
<td>-------------------------</td>
<td>---------</td>
<td>----------------</td>
<td>--------</td>
<td>-------------</td>
<td>---------------------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>------------------</td>
<td>------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td>-------------------------------------</td>
</tr>
<tr>
<td>McDonnell, 2009 [38]</td>
<td>USA</td>
<td>1</td>
<td>M</td>
<td>25</td>
<td>Fulminant hepatic failure</td>
<td>Tea-colored urine, fatigue, nausea, vomiting, aches, fever</td>
<td>Liver transplantation</td>
<td>No medical history</td>
<td>None</td>
<td>1.5 w</td>
</tr>
<tr>
<td>Melendez-Rosado, 2015 [39]</td>
<td>USA</td>
<td>1</td>
<td>F</td>
<td>42</td>
<td>Acute hepatitis</td>
<td>Abdominal pain, nausea, clamminess</td>
<td>Improvement</td>
<td>Hypertension; chronic kidney disease; diabetes mellitus type 2; chronic back pain; hemochromatosis; obesity</td>
<td>Hydralazine; hydrocodone/acetaminophen 7.5/325 mg every 4–6 h for back pain 3 days prior to admission</td>
<td>1 w</td>
</tr>
<tr>
<td>Narasimha, 2013 [26]</td>
<td>India</td>
<td>1</td>
<td>M</td>
<td>23</td>
<td>Mania</td>
<td>Extreme irritability, aggression, hallucinatory behavior, decreased sleep</td>
<td>Improvement</td>
<td>No medical history</td>
<td>NR</td>
<td>1 mo (1–2 capsules daily)</td>
</tr>
<tr>
<td>Nguyen, 2017 [27]</td>
<td>USA</td>
<td>1</td>
<td>F</td>
<td>22</td>
<td>Mania</td>
<td>Expansive mood, psychomotor agitation, disorganized and pressured speech, flight of ideas, grandiosity, delusions, auditory hallucinations</td>
<td>Hospitalization for 8 days and treatment with olanzapine 10 mg, lithium 300 mg 3 times per day and quetiapine 50–100 mg nightly for 1–3 mo</td>
<td>No medical history</td>
<td>Etonogestrel subdermal implant; 2 dietary supplements: G cambogia Plus™ (500 mg per capsule, 60% HCA); Cleanse and Detox® (raspberry ketones, licorice root, pumpkin seed, buckthorn root, Cascara sagrada, African mango, rhubarb, citrus pectin, acidophilus, Cape aloe)</td>
<td>1 w (1–3 capsules daily)</td>
</tr>
<tr>
<td>Roche, 2014 [18]</td>
<td>USA</td>
<td>1</td>
<td>F</td>
<td>67</td>
<td>Hypoglycemia</td>
<td>Syncope, hypoglycaemia</td>
<td>Improvement</td>
<td>Hypertension</td>
<td>Venlafaxine; lisinopril-hydrochlorothiazide; alprazolam</td>
<td>2 d</td>
</tr>
</tbody>
</table>
### Table 2 (continued)

<table>
<thead>
<tr>
<th>Article</th>
<th>Country</th>
<th>No of patients</th>
<th>Gender</th>
<th>Age (years)</th>
<th>Adverse event and diagnosis</th>
<th>Symptoms</th>
<th>Clinical outcome</th>
<th>Clinical history</th>
<th>Concomitant drugs</th>
<th>Exposure to GC before symptoms onset</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schoepfer, 2007</td>
<td>Switzerland</td>
<td>10</td>
<td>6 F 4 M</td>
<td>Mean 51 Range 30–69</td>
<td>Hepatotoxicity: 7 pts hepatic necrosis; 1 pt fulminant liver failure; 1 pt sinusoidal obstruction syndrome; 1 hepatocellular injury</td>
<td>Fatigue, loss of appetite, jaundice</td>
<td>1 pt improved after liver transplantation; 1 pt diagnosed with proven cirrhosis; 8 pts improved</td>
<td>1 pt positive for hepatitis A and B; 1 pt positive for hepatitis E; 1 pt with alcohol consumption (50 g/die)</td>
<td>At least 1 year before presentation: 1 pt amiloride/HCT; 1 pt cyproterone/etinyl estradiol; 1 pt ASA and diphenhydramine; 1 pt losartan</td>
<td>Median 5 mo</td>
</tr>
<tr>
<td>Shim, 2009 [41]</td>
<td>USA</td>
<td>1</td>
<td>M</td>
<td>28</td>
<td>Hepatotoxicity</td>
<td>Fatigue, dyspnea on exertion, jaundice, dark urine</td>
<td>Improvement</td>
<td>No medical history</td>
<td>Acetaminophen/ASA/caffeine 250/250/65 mg 4 times per day 10 d prior to admission</td>
<td>3 mo (4–6 tablets daily)</td>
</tr>
<tr>
<td>Sidhu, 2016 [21]</td>
<td>USA</td>
<td>1</td>
<td>M</td>
<td>36</td>
<td>Acute Pancreatitis</td>
<td>Left upper quadrant pain</td>
<td>NR</td>
<td>No medical history</td>
<td>NR</td>
<td>7 mo</td>
</tr>
<tr>
<td>Sikka, 2016 [19]</td>
<td>USA</td>
<td>1</td>
<td>F</td>
<td>59</td>
<td>Drug-induced immune thrombocytopenia; small subacute subdural hematoma</td>
<td>Painless GI bleed, abdominal and oral petechia, mild headache</td>
<td>CVA</td>
<td>NR</td>
<td>ASA</td>
<td>1 mo</td>
</tr>
<tr>
<td>Smith, 2016 [42]</td>
<td>USA</td>
<td>1</td>
<td>M</td>
<td>26</td>
<td>Liver failure, submassive hepatic necrosis</td>
<td>Icteric sclera and skin, fatigue</td>
<td>Liver transplantation</td>
<td>No medical history</td>
<td>Whey protein powder food supplement (1 w)</td>
<td>1 w (10 w prior to admission)</td>
</tr>
<tr>
<td>Stevens, 2005 [43]</td>
<td>USA</td>
<td>2</td>
<td>M</td>
<td>27</td>
<td>Acute liver injury</td>
<td>Fatigue, jaundice</td>
<td>Improvement</td>
<td>No medical history</td>
<td>None</td>
<td>5 w (9 tablets daily)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>M</td>
<td>30</td>
<td>Acute liver injury</td>
<td>Jaundice, fever, vomiting, fatigue</td>
<td>Improvement</td>
<td>No medical history</td>
<td>None</td>
<td>5 d (9 tablets daily)</td>
</tr>
</tbody>
</table>
Table 2 (continued)

<table>
<thead>
<tr>
<th>Article</th>
<th>Country</th>
<th>No of patients</th>
<th>Gender</th>
<th>Age (years)</th>
<th>Adverse event and diagnosis</th>
<th>Symptoms</th>
<th>Clinical outcome</th>
<th>Clinical history</th>
<th>Concomitant drugs</th>
<th>Exposure to GC before symptoms onset</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stickel, 2009</td>
<td>Switzerland</td>
<td>2</td>
<td>F</td>
<td>78</td>
<td>Severe hepatotoxicity; cholestatic and lobular/portal hepatitis</td>
<td>Nausea, painless jaundice, light stools, dark brown urine, pruritus</td>
<td>Improvement</td>
<td>Hypertension; hip endoprosthesis; appendectomy; cholecystectomy; alcohol consumption (60–80 g/w)</td>
<td>All treatments started more than 1 year prior to symptoms’ onset: irbesartan/HCT (300 mg/12.5 mg); carvedilol (25 mg); omeprazole 20 mg (occasionally); zolpidem 10 mg</td>
<td>3 year</td>
</tr>
<tr>
<td>F</td>
<td>50</td>
<td>Severe hepatotoxicity; cirrhosis</td>
<td>Weakness, painless jaundice and fluctuating lower abdominal pain intermittently for several years, pruritus</td>
<td>Improvement</td>
<td>Cholecystectomy; hysterectomy for myoma</td>
<td>None</td>
<td>1 year</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vitalone, 2016</td>
<td>Italy</td>
<td>1</td>
<td>F</td>
<td>39</td>
<td>Acute hepatitis</td>
<td>NR</td>
<td>Improvement</td>
<td>No medical history</td>
<td>None</td>
<td>NR</td>
</tr>
<tr>
<td>Wong, 2016</td>
<td>USA</td>
<td>1</td>
<td>M</td>
<td>43</td>
<td>Multiple psychotic symptoms</td>
<td>Auditory and visual hallucinations, paranoid thoughts, loss of appetite and sleep</td>
<td>Improvement</td>
<td>No medical history</td>
<td>5 food supplements: GC, Brain Support, Brain Awake®, a probiotic, Absorb-max™</td>
<td>NR</td>
</tr>
</tbody>
</table>
according to the same WHO criteria [46]. Finally, using the Drug-Induced Liver Injury Network (DILIN) study criteria [47], two cases were classified as probable, two possible, and five highly likely related to GC utilization [34].

Discussion

GC is a small fruit with traditional culinary use, and potential medicinal applications. In fact, several clinical interactions of GC have already been documented in the literature, for example, in the context of: appetite control [11, 48], neuroprotection [49], lipoproteins and cholesterol control [50], alterations in blood cell count [50], fat mass control [51], glucose metabolism [52], hormones regulation, and interactions with organ system (i.e., kidney) [53].

GC is a source of HCA (structurally related to citric acid), one of the isomers [(−)-hydroxycitric acid], which is thought to help in weight control [54]. The mechanism of action is inhibiting an enzyme called citric acid lyase, which is required in the synthesis of fatty acids. Preclinical evidence suggests that oral consumption of HCA reliably reduces food intake and body weight [51]. Studies in humans, for the most part, fail to replicate this. Some isolated studies do note weight loss, but it appears to be quite variable and unreliable.

Although there is some limited potential for HCA as a weight-loss inducer, the magnitude of effect is quite low, and the benefit is unreliable; making it hard to recommend this compound as a fat burner or anti-obesity agent. Beside poor evidence on GC efficacy as dietary compound, safety issues regarding this extract also represents a major clinical concern.

Present work suggests a potential causal association between consumption of GC products and development of acute liver injury. Although in some cases liver damage progressed slower than in others, this association is also supported by clinical outcomes of improvement after the cessation of dietary supplement intake. Symptoms of liver damage were similar in all patients, and were also confirmed, if available, by liver biopsies.

Length of GC treatment appears to be very heterogeneous among cases. However, given the lack of individual factors, such as comorbidities, concomitant treatment, and genetic factors, we were not able to evaluate the possible relationship between length of GC exposure and HILI severity, particularly for cases coming from the literature review.

Cavalieri et al. (2017) confirmed hepatitis, cholestasis accompanied with jaundice, pruritus, prominent elevation of alkaline phosphatase, and mild elevation of aminotransferases as clinical evidences of drug- and herb-induced hepatotoxicity [55].

HILI and drug-induced liver injury (DILI) are both caused by chemicals, but as HILI is primarily a human rather than an animal disease, experimental models to study in detail the mechanisms leading to injury are rarely available [56]. Usually, dietary supplements contain several ingredients, thus the substance specifically responsible for liver damage can be difficult to identify. Nevertheless, the case presented by Lunsford et al. (2016) was the first acute liver failure associated with a purified extract of GC, and as HCA was the main active principle of this kind of extract, it was the first substance to be suspected [37].

The HCA mechanism of toxicity on the liver is not clearly defined. In 2007, a study conducted in Houston (USA) shows that Super CitriMax (HCA-SX), a salt of (−)-hydroxycitric acid, reduces food intake, weight gain, and also attenuates the increase of inflammation, oxidative stress, and insulin resistance in obese rats [57]. Kim and colleagues (2013) studied the long-term effect of GC extract in obese mice, but find conflicting results [58]. The supplementation of GC confirms the action in weight control, significantly lowering visceral fat accumulation and adipocyte size by the inhibition of fatty acid synthesis and enhancing fatty acid β-oxidation. However, HCA increases hepatic collagen accumulation, lipid peroxidation, mRNA levels of genes related to oxidative stress (superoxide dismutase and glutathione peroxidase), and inflammatory responses (tumor necrosis factor-α and monocyte chemoattractant protein-1). Furthermore, GC-supplemented mice exhibit impaired liver function showing elevated plasma ALT and AST levels. Oxidative stress plays an important role in progression of steatohepatitis and hepatocellular injury [59]. In fact, reactive oxygen species can damage DNA, lipids, and proteins, inducing necrosis and apoptosis of hepatocytes and promoting inflammatory response.

Evidence highlights that the percentage of women attempting to control weight using dietary supplements is higher than that of men. In fact, all Italian cases herein described and the majority of patients (62%) described in the literature review were women. It is well-known that the percentage of women dissatisfied with their current weight and attempting to lose weight is also higher than that of men [60]. This might be explained by the common desire for a perfect body and thinness among women [60]. In this context, we believe that healthcare professionals (physicians, pharmacists, dieticians, herbalists, etc.) should pay particular attention to women, who represent the population with the higher use of herbal preparations, and thus the higher risk of potential related AEs [60].

Furthermore, certain patients could have genetic predisposition leading to hepatotoxicity, such as cytochrome P450 polymorphisms promoting toxic accumulation of metabolites [61–64]. Several liver diseases (e.g., hepatitis, cirrhosis, etc.) that are possible alternative causes for liver damage
were excluded both for our patient and for the majority of cases reported in the literature.

The risk of herb–drug interaction (HDI), a well-recognized public health problem leading to AEs, could not be excluded in all reported cases [65]. Concomitant intake of herbal supplements and prescribed medications is very commonly reported in patients suffering from chronic diseases, and HDI has been documented in several observational studies and case reports [66–68].

Currently, the harmful potential of herbal supplements is not systematically investigated before the products are made available to the general population. This lack of information compounded the difficulties in event-reporting and history-taking concerning herbal supplement composition and use [64].

In a prospective study conducted in the United States, herbal and dietary supplements are found to be implicated in 10% of DILI cases [69]. A double-blind, randomized crossover trial performed in Australia on 8 diabetic patients and 12 healthy subjects who received intraduodenal infusion of HCA, did not detect differences in sensations of hunger, fullness, and nausea between HCA patients and control individuals [70]. Al-kuraishy and colleagues (2016) studied the effect of orlistat alone and in combination with GC in 99 obese male patients randomized to orlistat alone (120 mg/die), GC in capsules (166 mg/die) and a third group treated with both orlistat and GC. All groups included 33 subjects. Compliance with treatment was defined as good, but in the GC treated group, patients reported side effects: headache (12 patients), heartburn (9), constipation (5), abdominal pain (4), flatulence (2), and diarrhea (3) [71]. In 2014, 60 overweight Brazilian women were randomized in two groups to receive standardized GC extract (2.4 g/die) or placebo for 60 days. During the treatment, the analysis of hepatic transaminases and creatinine clearance did not show signs of acute toxicity. Mainly the AEs reported during treatment with GC extract were gastric discomfort, increased evacuation, and nausea [72]. A literature review published in 2012 analyzed a total of 13 studies that report the midterm effects of HCA administration (equivalent dose range 1500–4667 mg/day) in a total of 930 subjects. None of these papers find serious AEs attributable to the intake of GC extract: the main side effects were nausea and headache. Generally, there were no differences between patients treated with GC and control subjects in side effects frequency. Only one of the studies included reported leg cramps, heartburn, diarrhea, flatulence, increased appetite, headaches, stomach burn, and menstrual disorders [54].

Although evidence coming from the present work suggests a potential causal association between GC products exposure and development of HILI, our findings are limited by the lack of data on factors influencing the severity of HILI, as drug–drug interactions, HDIs, and presence of acute on chronic liver injury (i.e., non-alcoholic steatohepatitis), especially for cases derived from the literature.

Therefore, further research is required to elucidate the efficacy and safety of GC long-term use in humans and, at the meantime, caution is needed when using GC supplements for weight management.

**Conclusion**

The constant influx of newly developed drugs and a growing risk from unfamiliar herbal and dietary supplements are making HILI an increasing and significant clinical challenge that can lead to acute liver failure, and to the requirement for liver transplantation. Although herbal hepatotoxicity is of great clinical and regulatory importance, lack of a stringent causality assessment remains a major issue for patients with suspected HILI. Since most studies in humans have been conducted on small samples and mainly in the short term, patients and healthcare professionals should be cautious when interpreting GC extracts efficacy and safety evidences available in literature. In this clinical context, further studies can be conducted to isolate, purify, and examine the effects of herbal active principles, especially because they are often used over the counter and with no medical supervision. Efforts might lead to an appropriate use of food supplements, as those taken for weight control, ensuring the best efficacy and safety for all patients, especially women. Continuous monitoring of herbal dietary supplements should be promoted to finally characterize their risk profile, thus supporting regulatory bodies for appropriate actions.

**Compliance with ethical standards**

**Conflict of interest** The authors declare that they have no conflict of interest.

**Statement of human and animal rights** This article does not contain any studies with human participants or animals performed by any of the authors.

**Informed consent** None.

**References**


